These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 30731016)
1. The Emerging Profile of Immunotherapy Approaches in the Treatment of AML. Daver N Oncology (Williston Park); 2019 Jan; 33(1):28-32. PubMed ID: 30731016 [No Abstract] [Full Text] [Related]
3. The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients. Pagano L; Fianchi L; Caira M; Rutella S; Leone G Oncogene; 2007 May; 26(25):3679-90. PubMed ID: 17530021 [TBL] [Abstract][Full Text] [Related]
4. An overview of the potential strategies for NK cell-based immunotherapy for acute myeloid leukemia. Sinha C; Cunningham LC Pediatr Blood Cancer; 2016 Dec; 63(12):2078-2085. PubMed ID: 27535002 [TBL] [Abstract][Full Text] [Related]
5. Immunotherapeutic strategies for relapse control in acute myeloid leukemia. Martner A; Thorén FB; Aurelius J; Hellstrand K Blood Rev; 2013 Sep; 27(5):209-16. PubMed ID: 23871358 [TBL] [Abstract][Full Text] [Related]
6. Developmental approaches in immunological control of acute myelogenous leukaemia. Torelli GF; Orsini E; Guarini A; Kell J; Foà R Best Pract Res Clin Haematol; 2001 Mar; 14(1):189-209. PubMed ID: 11355931 [TBL] [Abstract][Full Text] [Related]
7. Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia. Laing AA; Harrison CJ; Gibson BES; Keeshan K Exp Hematol; 2017 Oct; 54():40-50. PubMed ID: 28668350 [TBL] [Abstract][Full Text] [Related]
8. [The role of gemtuzumab ozogamicin in the treatment of acute myeloid leukemia patients]. Sakamaki H Gan To Kagaku Ryoho; 2008 Sep; 35(9):1629-34. PubMed ID: 18799927 [TBL] [Abstract][Full Text] [Related]
9. Ab therapy of AML: native anti-CD33 Ab and drug conjugates. Jurcic JG Cytotherapy; 2008; 10(1):7-12. PubMed ID: 17917880 [TBL] [Abstract][Full Text] [Related]
10. Antigen-specific immunotherapies for acute myeloid leukemia. Buckley SA; Walter RB Hematology Am Soc Hematol Educ Program; 2015; 2015():584-95. PubMed ID: 26637776 [TBL] [Abstract][Full Text] [Related]
11. Novel drug targets in acute leukemia. Stock W Clin Adv Hematol Oncol; 2015 Aug; 13(8):493-5. PubMed ID: 26351809 [No Abstract] [Full Text] [Related]
12. New approaches for the immunotherapy of acute myeloid leukemia. Geiger TL; Rubnitz JE Discov Med; 2015 Apr; 19(105):275-84. PubMed ID: 25977190 [TBL] [Abstract][Full Text] [Related]
13. Treatment of minimal residual disease in acute myelogenous leukemia (AML): focus on immunotherapeutic options. Simonsson B Leukemia; 1996 Jun; 10 Suppl 2():s44-5. PubMed ID: 8649052 [No Abstract] [Full Text] [Related]
14. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy. Acheampong DO; Adokoh CK; Asante DB; Asiamah EA; Barnie PA; Bonsu DOM; Kyei F Biomed Pharmacother; 2018 Jan; 97():225-232. PubMed ID: 29091870 [TBL] [Abstract][Full Text] [Related]
15. The role of various interleukins in acute myeloid leukemia. Kaser EC; Zhao L; D'mello KP; Zhu Z; Xiao H; Wakefield MR; Bai Q; Fang Y Med Oncol; 2021 Apr; 38(5):55. PubMed ID: 33835290 [TBL] [Abstract][Full Text] [Related]
16. The progress and current status of immunotherapy in acute myeloid leukemia. Yang D; Zhang X; Zhang X; Xu Y Ann Hematol; 2017 Dec; 96(12):1965-1982. PubMed ID: 29080982 [TBL] [Abstract][Full Text] [Related]
17. Update on antigen-specific immunotherapy of acute myeloid leukemia. Buckley SA; Walter RB Curr Hematol Malig Rep; 2015 Jun; 10(2):65-75. PubMed ID: 25896530 [TBL] [Abstract][Full Text] [Related]